Immunic Inc is to test its lead anti-inflammatory product IMU-838 as a potential COVID-19 therapeutic after preclinical studies showed the small molecule drug was active against the coronavirus SARS-CoV-2. Separately, the company has announced the pricing of a new share issue which is expected to yield a net $14 million.
